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A B S T R A C T
Objective: Psychological distress has a high impact on quality of life in patients with multiple sclerosis (MS),
Parkinson's disease (PD), and Huntington's disease (HD). Studies have shown that cognitive behavioral therapy
(CBT) and mindfulness-based therapies (MBTs) are successful in reducing psychological distress in patients with
anxiety, depressive, and chronic somatic disorders. We aimed to investigate the effectiveness of these therapies
in MS, PD, and HD patients.
Methods: We performed a comprehensive literature search in PubMed, PsycINFO, Embase and the Cochrane
Central Register of Controlled Trials up to March 2018. Randomized controlled trials (RCTs) investigating a CBT
or MBT and reporting psychological outcome measures were included. Two separate meta-analyses were per-
formed; one on studies comparing psychological therapy with a treatment as usual or waitlist condition and one
on studies with active treatment control conditions.
Results: The first meta-analysis (N=12 studies, 8 in MS and 4 in PD populations) showed a significant effect size
of g=0.51 in reducing psychological distress. The second meta-analysis (N=7 studies, in MS populations)
showed a mean effect size of g=0.36. No RCTs were found in HD populations. The overall quality of the
included studies was low and considerable heterogeneity was found. No evidence was found for publication bias.
Conclusion: CBT and MBTs have a small to moderate effect on reducing psychological distress in patients with PD
and MS. However, more research with better methodological quality and larger study samples is warranted,
especially in HD patient populations.
1. Introduction
Progressive neurological disorders, such as Multiple Sclerosis (MS),
Parkinson's disease (PD) and Huntington's disease (HD), are often ac-
companied by psychological distress [1–3]. Psychological distress can
be defined as negative mental health states and includes anxiety and
depressive symptoms. Psychological distress has a higher impact on the
quality of life of both the patients and their caregivers as compared to
the physical symptoms that accompany the diseases [4,5].
The resemblance between MS, PD and HD includes the progressive
nature of the disease, uncertainty on disease course, and incurability
(only symptom reduction is possible), which contribute to psycholo-
gical distress. In addition to these factors, psychological distress can
arise from physical symptoms such as spasms, rigidity, and autonomic
dysregulation, resulting in a vicious circle where physical and psycho-
logical symptoms reinforce one another. On the neurobiological level,
frontostriatal circuits are affected by the disease, causing disruptions in
cognition, affect, motivation, behavior, and stress regulation [6,7].
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Because of these similarities, it is likely that these three patient popu-
lations can equally benefit from psychological treatments. This hy-
pothesis is supported by the finding that a standardized psychosocial
self-management program proved to be effective in a variety of chronic
diseases, including MS, PD, and HD [8].
A considerable number of studies has investigated potential effec-
tive treatments for psychological distress reduction. These treatments
are cognitive behavioral and mindfulness-based. In an extensive review
and meta-analysis, Hofmann and colleagues [9], showed that cognitive
behavioral therapy (CBT) is an effective treatment for psychological
distress and, more specifically, anxiety symptoms in patients with
psychiatric and medical conditions. Besides classical CBT, problem
solving and self-management therapies are also considered CBT-based
since these interventions are based on the same principles. In PD pa-
tients, CBT also showed positive effects in treating anxiety and de-
pressive symptoms [10–12]. In MS, Dennison and colleagues [13]
concluded that CBT is effective in improving the management of so-
matic symptoms and psychological distress. According to Novak and
Tabrizi [14], depression and anxiety are usually treated with medica-
tion in HD patients, but CBT is also effective in well-selected patients
that experience mild symptoms and who have insight in their psycho-
logical problems. However, no controlled studies have been performed
in this patient group.
Besides CBT, mindfulness-based treatments (MBTs) receive in-
creasing attention in clinical practice. Mindfulness involves ‘paying
attention in a particular way: on purpose, in the present moment, and
non-judgmentally’ [15]. MBTs include mindfulness-based stress reduc-
tion, mindfulness-based cognitive therapy, meditation, and acceptance
and commitment therapy. MBTs have been proven to be effective in
reducing anxiety and depressive symptoms in patients with anxiety and
depressive disorders [16], and patients with chronic pain [17]. Also,
small to moderate effect sizes in improving mental health were found in
populations with different chronic somatic diseases [18,19], and
medium effect sizes were found in MBTs for MS patients [20].
To reduce psychological distress in patients with progressive neu-
rological disorders, CBTs and MBTs might thus be of potential benefit.
Since these interventions are considered treatment options, it is war-
ranted to investigate their effectiveness. In order to establish the effi-
cacy of CBTs and MBTs on reducing psychological distress in PD, HD,
and MS patients, we performed a meta-analysis on randomized con-
trolled trials.
2. Method
2.1. Selection of studies
A comprehensive literature search was conducted in PubMed,
PsycINFO, the Cochrane library and EMBASE through March 2018. In
addition, ClinicalTrials.gov was searched for completed but unpublished
studies. The following keywords were used: “Parkinson”, “Huntington”,
“Multiple Sclerosis”, “psychological distress”, “stress reduction”, “dis-
tress”, “depressive symptoms”, “anxiety symptoms” (see the supple-
mentary material for the complete search string). Besides the database
searches, recent meta-analyses [21–23] were read to find additional
studies. Two researchers (IG, SR) independently selected the studies for
inclusion and when they disagreed a consensus was made.
Inclusion criteria for the meta-analyses were:
- Patients: a study population of MS, PD, or HD patients.
- Intervention: the examination of a CBT- or MBT-based intervention.
- Comparison: the intervention was compared with a waitlist or
treatment-as-usual (TAU) condition, or with another active form of
therapy. Only randomized controlled trials (RCTs) were included in
this meta-analysis.
- Outcome: availability of questionnaires that measure anxiety and/or
depressive symptoms, or general mental health. These data should
allow the calculation of standardized mean differences (post-treat-
ment means, standard deviations, and number of participants; or
other statistics that allowed to calculate effect sizes).
The study abstract or manuscript should be available in English or
Dutch.
2.2. Data extraction
All decisions on the inclusion of outcome measures for psycholo-
gical distress, including depressive and anxiety symptoms, or/and
general mental health outcome measures, were based on consensus
between two researchers (IG, SR). Outcome measures of psychological
distress were extracted by these two researchers, independently. Post-
treatment measurements were collected to examine the immediate ef-
fect of the interventions. When data were not available, the study re-
searchers were contacted. In addition, two independent researchers
(RB, MH) rated the type of interventions (CBT or MBT) investigated in
the studies, based on the treatment components described in the
manuscript.
2.3. Quality assessment
The methodological quality of the included studies was assessed
with seven criteria of the risk of bias assessment tool, developed by
Cochrane [24] to assess sources of bias in RCTs:
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding of participants and researchers (performance bias)
4. Blinding of outcome assessment (detection bias)
5. Incomplete outcome data (attrition bias)
6. Selective reporting (reporting bias)
7. Other bias
When questionable or unclear risk of bias was found, this was
considered a risk of bias.
Again, quality assessment was performed by two independent re-
searchers (IG, SR).
2.4. Meta-analyses
The Hedges' g effect sizes were calculated for each study and pooled
with Comprehensive Meta-analysis (CMA; version 3 for Windows).
Post-treatment means and corresponding standard deviations measures
were used to calculate Hedges' g. Means and standard deviations from
anxiety, depression, and general mental health outcome measures
within each study were pooled within the CMA program so that one
‘psychological distress’ measure for each study was included in the
meta-analyses. Two separate main meta-analyses were conducted: the
first to investigate CBTs and MBTs that were compared with waitlist or
TAU conditions, the second to investigate CBTs and MBTs that were
compared with other active interventions (such as supportive listening,
relaxation, and psycho-education).
Within the first main meta-analysis, besides the combined psycho-
logical distress measure, the individual effect sizes on anxiety, depres-
sion, and general mental health outcomes were investigated using se-
parate smaller meta-analyses. Subgroup analyses were conducted for
disease type, control condition, and high vs low risk of bias. In addition,
the relationship between risk of bias and effect size was investigated
with a regression analysis. Within the second main meta-analysis, the
different types of interventions of interest (CBTs and MBTs) were in-
vestigated by performing two separate meta-analyses. There were too
few studies to perform further subgroup analyses.
As considerable heterogeneity was expected, all analyses were
conducted using the random effects model. The I2 statistic was
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calculated as an indicator of heterogeneity. We calculated the 95%
confidence intervals (95% CI) around I2 [25] using the non-central chi-
squared based approach within the heterogi module for Stata [26].
When the I2 estimate reached 40%, this was classified as considerable
heterogeneity [27].
Subgroup analyses were conducted according to the mixed-effects
model [28], and the meta-regression analysis was conducted according
to the procedures developed by Borenstein et al. [28].
Publication bias was examined with Duval and Tweedie's trim and
fill procedure which estimates how many studies are missing in the
meta-analyses and then imputes these [29], as well as Egger's test for
the asymmetry of the funnel plot.
The protocol of this meta-analysis was not pre-registered.
3. Results
3.1. Selected studies
After removing duplicate studies, 156 records were found. After
inspection of the titles and abstracts, 24 full-text articles were retrieved.
In addition, four studies were included from past meta-analyses, re-
sulting in 28 full-text articles that were read. Fig. 1 presents the flow-
chart of the inclusion process with reasons for exclusion, following the
PRISMA statement [30]. Eventually, 19 studies were included, of which
12 were included in the first meta-analysis, and seven in the second
meta-analysis.
3.2. Characteristics of included studies
Table 1 shows the characteristics of the included studies, displayed
separately for the two main meta-analyses. Within the first analysis,
eight studies included MS patients [31–38], four studies included PD
patients [39–42], and no RCTs were found investigating HD popula-
tions. Nine studies examined a CBT-based intervention
[31,33–37,39,41,42] and three studies investigated an MBT [32,38,40].
Within the second analysis, only MS patients were investigated in
the included studies. Regarding the treatments of interest, four studies
investigated a CBT-based treatment [43–46] and three examined an
MBT [47–49].
Overall, the quality of the included RCTs was low, based on the
scores on the risk of bias assessment tool. Blinding of participants/re-
searchers was impossible due to the nature of studies on psychother-
apeutic interventions, and was therefore always considered as risk of
bias. As allocation concealment was often not well reported, two studies
had a risk of detection bias [41,47]. The study by Okai and colleagues
[41] also showed an attrition bias, as did the study by Calleo and col-
leagues [39]. In the first analysis, four studies showed good quality
[31,33,38,42], as shown by a total risk of bias of 1 (only risk of per-
formance bias). In the second analysis, only the study by Carletto and
colleagues had good quality (score of 1 on the risk of bias assessment
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Fig. 1. PRISMA flow chart of selection and inclusion process. CBT=Cognitive Behavioral Therapy, MBT=Mindfulness Based Therapy; RCT= randomized con-
trolled trial.
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3.3. Treatment effects
• Meta-analysis 1: CBTs and MBTs versus TAU or waitlist condition
Fig. 2 displays the forest plot of the standardized effect sizes of
psychological therapies on psychological distress in PD and MS pa-
tients, compared with a waitlist or TAU condition. The mean effect size
(g) was 0.51 (95% CI=0.22–0.80) with a heterogeneity estimate (I2) of
66 (95% CI=27–80).
As a post-hoc analysis, the studies of Okai et al. [41], Ghielen et al.
[40], and Kiropoulos et al. [35] were excluded in a separate meta-
analysis. These studies were considered outliers since the effect sizes
with their 95% confidence intervals were outside the 95% confidence
interval of the pooled main effect size. The effect size decreased to
g=0.31 (95% CI=0.13–0.48) and heterogeneity decreased to I2= 0
(95% CI=0–56) when these three studies were removed (see Table 2).
To investigate the treatment effects on the different types of out-
come measure separately, three meta-analyses were conducted on an-
xiety, depression, and general psychological distress outcome measures.
The treatment effect on general mental health outcomes was highest
(g=0.79, 95% CI= 0.32–1.25 with I2= 66, 95% CI=0–85), followed
by the effect on anxiety symptoms (g=0.36, 95% CI=0.03–0.66 with
I2= 59, 95% CI=0–79), and depressive symptoms (g=0.33, 95%
CI= 0.05–0.62 with I2= 60, 95% CI=0–78) (see Table 2).
In addition, subgroup analyses were conducted (Table 2) to in-
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MS=Multiple Sclerosis, PD=Parkinson's Disease, CBT=Cognitive Behavioral Therapy, MBSR=Mindfulness Based Stress Reduction, ACT=Acceptance &
Commitment Therapy, IPST= Internet-based Problem Solving Therapy, BAM=Body-Affective Mindfulness, PT=Physical Therapy, WL=Wait-List, PE= Psycho-
Education, SL= Supportive Listening, TAU=Treatment As Usual, HADS=Hospital Anxiety and Depression Scale (A= anxiety, D= depression), BDI=Beck
Depression Inventory, PSS= Perceived Stress Scale, GHQ=General Health Questionnaire, PHQ=Patient Health Questionnaire, NPI=NeuroPsychiatric Inventory,
POMS=Profile Of Mood Scale, GSES=General Self-Efficacy Scale, BAI=Beck Anxiety Inventory, HRSD=Hamilton Rating Scale for Depression
a Risk of bias is derived after assigning a zero (low risk of bias (0)) or one (unclear (?) or high risk of bias (1)) to each one of the following quality criteria:
allocation sequence, allocation concealment, blinding of participants and personnel, blinding of assessors, incomplete outcome data, selective reporting, and other
sources of bias, and a sum score.
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and risk of bias (high vs low). Significantly larger effect sizes were
found in MS patient populations, TAU control condition, and studies
with a high risk of bias.
Meta-regression analyses on risk of bias (β=0.08, 95%
CI=−0.18–0.33, p > .05) did not show a significant relationship
with effect size.
• Meta-analysis 2: CBTs and MBTs versus active control condition
Fig. 3 shows the forest plot of the standardized effect sizes of psy-
chological therapies on psychological distress in MS patients, compared
with an active control condition. The mean effect size (g) was 0.36
(95% CI=0.13–0.58) with a heterogeneity estimate (I2) of 40 (95%
CI= 0–74).
To investigate the treatment effects for the types of investigated
intervention, two separate meta-analyses were conducted on CBT-based
treatments and MBTs. The treatment effect for CBT-based treatments
was highest (g=0.45, 95% CI= 0.26–0.64 with I2= 0, 95%
CI= 0–73), followed by a small effect for MBTs (g=0.06, 95%
CI=−0.56–0.68 with I2= 68, 95% CI= 0–89) (see Table 2).
• Publication bias
No evidence for publication bias was found in both meta-analyses.
Study name Disease Therapy Control Statistics for each study Hedges’ g and 95% CI
Hedges’ g Lower limit Upper limit p-value 
Boeschoten et al. (2016) [31] MS IPST WL 0.11 -0.21 0.42 0.51 
Bogosian et al. (2015) [32] MS Mindfuln WL 0.55 -0.10 1.20 0.10 
Fischer et al. (2013) [33] MS CBT WL 0.32 -0.09 0.74 0.12 
Forman et al. (2010) [34] MS CBT WL 0.41 -0.22 1.04 0.20 
Kiropoulos et al. (2016) [35] MS CBT TAU 1.64 0.83 2.46 <0.001 
Lincoln et al. (2011) [36] MS CBT WL 0.38 0.04 0.73 0.03 
Mohr et al. (2000) [37] MS CBT TAU 0.57 -0.12 1.26 0.11 
Simpson et al. (2017) [38] MS MBSR WL 1.04 0.46 1.62 <0.001 
Calleo et al. (2015) [39] PD CBT TAU 0.11 -1.01 1.24 0.84 
Ghielen et al. (2016) [40] PD ACT+PT TAU -0.45 -1.08 0.18 0.16 
Okai et al. (2013) [41] PD CBT WL 1.44 0.71 2.17 <0.001 
Troeung et al. (2014) [42] PD CBT WL 0.36 -0.56 1.27 0.46 
0.51 0.22 0.80 0.001 
-1.0 0 1.0 2.0 
Favours control Favours therapy 
Fig. 2. Forest plot of studies comparing CBTs and MBTs with TAU or WL conditions (meta-analysis 1). MS=Multiple Sclerosis; PD=Parkinson's disease;
IPST= Internet-based Problem Solving Therapy; Mindfuln=Mindfulness; CBT=Cognitive Behavioral Therapy; MBSR=Mindfulness Based Stress Reduction;
ACT=Acceptance & Commitment Therapy; PT=Physical Therapy; TAU= treatment as usual; WL=waitlist.
Table 2
Effect sizes and heterogeneity measures for CBTs and MBTs in improving psychological distress in PD and MS patients, including subgroup analyses.
N (studies) Hedges'g 95% CI I2 95% CI p-value NNTa
Meta-analysis 1
All 12 0.51 0.22–0.80 66 27–80 <0.001 3.55
Excluding outliers@ 8 0.31 0.13–0.48 0 0–56 0.008 5.75
Outcome
Depression 10 0.33 0.05–0.62 60 0–78 0.042 5.43
Anxiety 8 0.36 0.03–0.68 59 0–79 0.038 5.00
Psychological distress 5 0.79 0.32–1.25 66 0–85 0.015 2.36
Subgroup analyses
Disease type
MS 8 0.54 0.26–0.82 45 0–72 0.003 3.36
PD 4 0.37 −0.55–1.29 80 16–91 4.85
Control condition
Waitlist 7 0.39 0.18–0.60 26 0–68 0.006 4.59
TAU 5 0.67 −0.16–1.49 82 49–91 2.75
Risk of Bias #
High 8 0.57 0.14–0.99 71 22–84 0.003 3.18
Low 4 0.42 0.02–0.81 61 0–85 4.27
Meta-analysis 2
All 7 0.36 0.13–0.58 40 0–74 0.002 5.00
Treatment type
CBTs 4 0.45 0.26–0.64 0 0–73 0.004 3.55
MBTs 3 0.06 −0.56–0.68 68 0–89 0.72 29.41
MS=Multiple Sclerosis; PD=Parkinson's Disease; CBTs=Cognitive Behavioral Therapies; MBTs=Mindfulness Based Therapies; NNT=Number Needed to Treat;
TAU= treatment as usual. aaccording to Kraemer & Kupfer [50].@ outliers include Okai et al. [41], Kiropoulos et al. [35], Ghielen et al. [40]. # low risk of bias
include studies scoring 1 according to the risk of bias assessment tool, developed by Cochrane [24], a score > 1 is considered high risk of bias.
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Inspection of the funnel plots did not indicate significant publication
bias (Figs. 4 & 5). Duval & Tweedie's trim-and-fill procedure resulted in
the imputation of four studies in the first meta-analysis, and no
imputations in the second meta-analysis, according to a random model.
Egger's regression intercept indicated no significant publication bias
(p > .05 in both analyses).
Study name Disease Therapy Control Statistics for each study Hedges’ g and 95% CI
Hedges’ g Lower limit Upper limit p-value 
Ehde et al. (2015) [43] MS Self-
management 
PE 0.35 0.04 0.66 0.03 
Mohr et al. (2001) [44] MS CBT Supportive 
expression 
0.51 -0.10 1.11 0.10 
Mohr et al. (2005) [45] MS MBSR PE 0.39 0.03 0.74 0.03 
Moss-Morris et al. (2013) [46] MS CBT SL 0.69 0.27 1.12 0.001 
Nordin et al. (2012) [47] MS ACT Relaxation -0.10 -0.93 0.73 0.81 
Oreja-Guevera et al. (2015) [48] MS MBSR PE -0.37 -0.98 0.23 0.23 
Carletto et al. (2017) [49] MS BAM SL 0.53 0.11 0.96 0.01 
0.36 0.13 0.58 0.002 
-1.0 0 1.0 2.0 
Favours control Favours therapy 
Fig. 3. Forest plot of studies comparing CBTs and MBTs with active control conditions (meta-analysis 2). MS=Multiple Sclerosis; CBT=Cognitive Behavioral
Therapy; MBSR=Mindfulness Based Stress Reduction; ACT=Acceptance & Commitment Therapy; PE=Psycho-Education; SL= Supportive Listening.
Fig. 4. Funnel plot of meta-analysis 1: CBTs and MBTs versus TAU or WL conditions. CBT = Cognitive Behavioral Therapy; MBT = Mindfulness Based Therapy;
TAU= treatment as usual; WL=waitlist. The imputed studies are shown in black.
Fig. 5. Funnel plot of meta-analysis 2: CBTs and MBTs versus active control conditions. CBT = Cognitive Behavioral Therpay; MBT = Mindfulness Based Therapy.
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4. Discussion
In this study, we investigated the effectiveness of CBT and MBT on
psychological distress in patients with PD and MS by conducting two
main meta-analyses of randomized controlled trials. There were no
RCTs found studying these therapies in HD populations. Nineteen stu-
dies were included in the analyses, of which twelve compared the
treatment of interest with a TAU or waitlist condition (meta-analysis 1),
and seven studies compared the treatment of interest with an active
control condition (meta-analysis 2). A moderate effect size (g=0.51)
was found in the first meta-analysis, and a small effect size (g=0.36)
was found in the second meta-analysis. In both meta-analyses there was
considerable heterogeneity, which was probably due to the variability
in hours of treatment (range: 5–16 h), different delivery forms (for ex-
ample by telephone or face-to-face), differences in comorbidity in the
included subjects over all included studies, and specific elements that
varied between the interventions (such as psycho education in the study
of Okai et al. [41]). The heterogeneity decreased when 1) outliers were
removed; 2) depression and anxiety outcomes were analyzed sepa-
rately; 3) only looking at MS patient samples; 4) studies with waitlist
control conditions were analyzed; and 5) studies with a low risk of bias
were analyzed. In these post-hoc analyses, the effect sizes decreased to
small (g=0.31, g=0.33, g=0.36, g=0.39, g=0.42, respectively).
No evidence was found for publication bias.
The small to moderate main effect sizes suggest that CBT and MBT
are beneficial in reducing psychological distress, but only to a certain
extent. Biological approaches, e.g. pharmacotherapy, showed a reduc-
tion of depressive symptoms in MS patients with an effect size of 0.63
(standardized mean difference) [22]. According to the review and
meta-analysis by Fiest et al. [22], current research is insufficient to
determine the effectiveness of pharmacotherapy for anxiety in MS as no
controlled studies were found. In PD, the meta-analysis of Bomasang
and colleagues [51] on antidepressant medication showed an effect size
of 0.54 in reducing depressive symptoms. The effect of pharma-
cotherapy on reducing symptoms of anxiety in PD patients has in-
sufficiently been studied. Although the effect sizes of pharmacotherapy
on depressive symptoms appear to be larger than those of psychological
treatment, regarding anxiety and global mental health the effect is not
yet investigated properly. One can imagine that pharmacological in-
terventions show larger effect sizes compared to psychotherapeutic
interventions, since the latter requires cognitive abilities to learn and
apply the methods that are taught. Although patients with dementia
were excluded in most studies, it is possible that these populations have
reduced cognitive abilities as a result of the neurodegenerative process,
and are therefore unable to optimally benefit from CBT and MBT. It is
also argued that a combination of psychotherapy and pharmacotherapy
might be most beneficial, at least for outpatients with chronic forms of
depression [52,53] and panic disorder [53]. In adults with an anxiety or
depressive disorder without neurological comorbidity, a meta-analysis
of Cuijpers and colleagues [54] showed that CBT is probably effective.
Although effect sizes were larger (around g=0.80) compared to our
results, the quality of the included studies was low and publication bias
was present. Large effect sizes were also found for MBTs in the treat-
ment of anxiety and depressive symptoms in participants without
neurological comorbidity [55]. Here, no publication bias was present
but study quality was again unsatisfactory. CBT and MBT appear to be
more effective in patients without compared to patients with neuro-
degenerative disorders. However, the methodological quality is in-
sufficient to draw definite conclusions.
MS patients seem to benefit more from CBT and MBT than PD pa-
tients as is represented by the significant subgroup difference in effect
size regarding disease type. However, considerable heterogeneity was
present in both subgroups and all therapies described here were
adapted to the respective study sample. The MS population is best re-
presented in these meta-analyses, including fifteen RCTs of which eight
were included in the first meta-analysis. The second meta-analysis
included only studies in MS populations. Overall, the mean age of MS
patient groups was lower compared to the PD patient groups. One can
imagine that having a progressive neurological disorder in an earlier or
later phase of life results in different psychosocial issues and cognitive
abilities to benefit from therapy.
A considerably large effect size was found in the pilot study of Okai
and colleagues [41]. In this study, all PD patients additionally suffered
from impulse control disorders. When the treatment components were
critically investigated, it was notable that this was the only CBT-based
intervention that included executive dysfunction education. PD patients
often show an impairment in executive functioning in an early stage of
the disease [56,57]. Since this study showed a great improvement in
psychological distress, this might indicate that executive dysfunction
plays an important role in regulating negative emotions and cognitions,
at least in PD patients with impulse control disorders. This, however,
needs confirmation in future research.
The pilot study by Kiropoulos et al. [35] also showed a large effect
size (g=1.64). This study included newly diagnosed MS patients
(< 5 years since diagnosis) and the age of these patients was lower
compared to other studies that investigated MS populations. These
patients might be less severely affected compared to other study po-
pulations. Comparisons, however, could not be made since studies re-
ported different measures of disease severity. No differences were found
concerning treatment components when compared with other CBT-
based interventions in MS.
Of great importance is the focus of the treatment types and control
conditions. The studies by Ghielen et al. [40], Oreja-Guevera et al. [48],
and Nordin et al. [47] investigated MBTs. These three studies showed
(non-significant) negative effect sizes of g=−0.45, g=−0.37, and
g=−0.10, respectively, favoring the control condition in reducing
psychological distress symptoms. These studies all included an active
form of control condition: physical therapy (TAU), psycho education,
and relaxation, which might have diminished the positive effect. Be-
sides this, the focus of ACT is not on symptom reduction but on coping
with the disease despite of the symptoms that are present. This is
achieved by improving awareness of ones bodily sensations, thoughts
and feelings. As one can imagine, when one is more aware of his/her
symptoms, these will also be more often reported, resulting in a higher
score on questionnaires.
This leads us into the discussion concerning the suitability of
questionnaires to measure treatment effects. Since MBTs are focused on
awareness and acceptance, and not aim to reduce symptoms, ques-
tionnaires that measure the prevalence or severity of symptoms are less
appropriate. The studies by Bogosian et al. [32] and Simpson et al. [38],
however, investigated mindfulness interventions and showed effect
sizes of g=0.55 and g=1.04, respectively, in improving general
mental health. In addition, when overall psychological distress was
measured with general mental health questionnaires, a high effect size
of g=0.79, although with considerable heterogeneity, was found. The
focus of an intervention, type of control condition, and the outcome
measures used seem to be of importance in evaluating the effectiveness,
and therefore need to be carefully considered when conducting an RCT.
Overall, the included studies had low quality, only three out of se-
venteen studies reached good quality according to the risk of bias tool.
The findings need to be carefully interpreted since risk of bias is present
in most of the studies and might have influenced the treatment effects.
Each study suffers from different types of bias, except for the perfor-
mance bias which is always a risk due to the nature of these interven-
tion studies.
4.1. Limitations and implications
First, the effect size is solely based on studies in patients with PD
and MS, since there were no RCTs found in HD that investigated the
effect of psychological interventions on psychological distress. Second,
MS patients might be overrepresented in the meta-analysis since fifteen
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out of nineteen RCTs investigated MS populations, resulting in the ef-
fect size being driven mostly by MS populations, especially in the
second meta-analysis in which only MS populations were included.
Heterogeneity estimates were above 40% in most analyses, reflecting
high heterogeneity within the meta-analyses, and most studies included
small sample sizes, which resulted in low power. Finally, the overall
quality of the studies was low and the quality of one study could not be
assessed.
It is therefore recommended to study psychological interventions in
more detail and in larger patient samples in study designs with higher
methodological quality. Especially in HD more research is needed, since
no RCTs on the effects of psychological treatment were found in our
literature search. It might also be interesting to investigate the addition
of psychopharmacological therapies, besides psychotherapy. Besides a
primary focus on reducing psychological distress, we recommend to
investigate the effect on coping with the disease, quality of life, valued
living, or self-efficacy, especially in RCTs studying the effect of MBTs.
Since progression of the disease is inevitable, it is therefore important to
learn how to cope with the disease instead of focusing on symptom
reduction only. Furthermore, caution is warranted in the choice of
outcome measures and the type of control conditions as comparators,
since these decisions greatly influence the study outcome. Lastly, it
might be interesting to include executive dysfunction education in in-
terventions for PD patients with impulse control disorders.
4.2. Conclusion
Despite the abovementioned limitations, we conclude that CBTs and
MBTs have a small to moderate effect on reducing psychological dis-
tress in patients with PD and MS. However, more research is warranted,
especially in HD and PD patient samples. These studies need to have
better methodological quality (e.g. lower risk of bias) and study sam-
ples should be larger to achieve a sufficient power.
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